more effective diagnostics, prognostics, and treatment options are on, not beyond, the current horizon. Additionally, the payment structure for physicians and hospitals is rapidly changing.
It would not be hard to take the most nihilistic approach and argue that the current training and practice patterns of these new fellows will leave them in a position where it will be increasingly difficult to sustain their income. Other breast specialists will quickly be able to do almost everything that is currently in the areas covered by breast surgeons.
Radiologists dominate screening and diagnostic imaging. In many hospitals, radiologists and surgeons cooperate in sharing image-guided biopsy; in others, the sharing is done grudgingly or does not occur at all. It is fair to say that most radiologists are at least as capable as most surgeons in performing image-guided biopsies. Since they control the gateway to image-detected cancers, i.e. mammography and magnetic resonance imaging (MRI), the opportunity and need for surgeons is unclear and in jeopardy. Furthermore, open surgical biopsy is almost never needed and certainly cannot sustain a practice. In the US, the percentage of patients undergoing open surgical biopsy has declined from more than 75 % in the 1990s to less than 20 % in more contemporary series. 1 The National Accreditation Program for Breast Centers (NAPBC) Standard 2.9 states that ''Palpation-guided or image-guided needle biopsy is the initial diagnostic approach rather than open biopsy.'' While not all patients can have image-guided biopsies, the goal is somewhere around 90 %. Approximately 4-14 % of patients who have an imageguided vacuum-assisted biopsy receive a diagnosis of atypical hyperplasia. 3, 4 These patients now undergo open surgical biopsy. It is not hard to imagine that with advances in tumor genetics and profiling we will prove that the need for open surgical biopsy after a diagnosis of atypical hyperplasia by core biopsy is even more limited. Newer biopsy techniques and more intricate non-histologic analyses will give us the information that was once only possible with open operations.
We have made remarkable advances in chemotherapy and hormonal therapy, and the majority of even advanced cancers respond to neoadjuvant treatments. Advances in genomics and proteomics will certainly provide even better tools to describe personalized and more effective treatments that will drive down the need for surgical treatment of many breast cancers. After neoadjuvant therapy, small residual cancers may someday be treated with ablative percutaneous techniques that will be within the expertise of non-surgeons. Similarly, it is likely that we will discover which non-invasive breast diseases even need to be treated, further limiting the number of patients who will need breast operations.
As we come to better understand the genetics of breast cancer we will identify more women who stand to benefit from prophylactic mastectomies. While breast surgeons now do most of these operations, most of them do not do their own reconstructive operations. While it is comfortable to argue that breast surgeons are the most qualified to do these operations, that argument is self-serving and probably not valid. Most plastic surgeons who now control the majority of breast reconstructive operations are already doing breast reduction operations. It is hard to argue that they are not capable of performing prophylactic mastectomies.
While it can be fairly stated that surgeons are currently the first clinicians who see patients with breast disorders, it is not hard to envision other non-surgical or even nonphysician practitioners guiding patients into the system. As surgeons we feel that we are in the best position to guide patients from diagnosis through treatment; however, without the need to perform procedures, it will be hard, from a fiscal point of view, to maintain a viable practice.
The current payment system is designed to reward procedures, not cognitive aspects of care.
Breast specialists who have restricted their practice will face many obstacles if they find the need to return to general surgery. Credentialing Committees and Surgery Department Chairs (if they even exist in the future) will be understandably hesitant to allow a surgeon to take general surgery or trauma call after 10 years of a breast-only practice.
For all of these reasons we need to start planning the future of the surgical breast specialists. There may be a real danger that fellows who are training in 2016 will have a hard time paying their bills in 2026. We need to start considering how we can preserve the positive attributes of breast specialists in the quickly changing new future. Solutions that focus on counseling, physical examination, and guidance of breast patients will be inadequate. It is time to start a dialogue about where this area of specialization is headed.
